Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Dec 21, 2019
Date Accepted: Jun 3, 2020
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Virtual reality smartphone-based smoking cessation program: A pilot RCT on initial clinical efficacy and adherence
ABSTRACT
Background:
Obstacles to current tobacco cessation programs include limited access and adherence to effective interventions. Digital interventions offer a great opportunity to overcome these difficulties, yet virtual reality has not been used as a remote and self-administered tool to help increase adherence and effectiveness.
Objective:
This study aimed to evaluate participant adherence and smoking cessation outcomes in a randomized pilot trial of the digital intervention Mindcotine® utilizing a self-administered treatment using virtual reality combined with mindfulness.
Methods:
A sample of 120 participants was recruited in the City of Buenos Aires, Argentina (age M = 43.20 years, SD = 9.50; 57/120 (47.5%) female). Participants were randomly assigned to a treatment group (TG), which received a self-assisted 21-day program based on Virtual Reality Mindful Exposure Therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support moderated by psychologists; and a control group (CG), which received a smoking cessation manual from the Argentine Ministry of Health. Follow-up assessments were conducted by online surveys at days 1 and 90 post-intervention. The primary outcome was abstinence at day 1 follow-up, with missing data assumed as still smoking. Secondary outcomes included sustained abstinence at 90-day follow-up, adherence to the program, and readiness to quit.
Results:
Follow-up rates at day-1 were 93% (56/60) for the TG and 100% (60/60) for the CG. At day-1 follow-up, the TG reported 23.3% (14/60) abstinence on that day compared to 5.0% (3/60) in the CG. This difference was statistically significant (Chi2 (1) =8.3; P = .004). The TG reported sustained abstinence of 33% (20/60) at 90 days. Among participants still smoking at day-1 follow-up, the TG was significantly more ready to quit compared to the CG (TG: M = 7.71; SD = 0.13; CG: M = 7.16; SD = 0.13; P = 0.005). A total of 41.1% (23/56) of participants completed the treatment in the time frame recommended by the program.
Conclusions:
Results provide initial support for participant adherence and efficacy of Mindcotine® and warrant testing the intervention in a fully powered randomized trial. Further research is needed on ways to promote app engagement. Clinical Trial: ID ISRCTN50586181
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.